Navigation Links
Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Date:4/23/2008

atent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Idenix Pharmaceuticals Contact:

Teri Dahlman (617) 995-9905


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... and BOSTON , May 29, ... instrument development, custom automation, and contract manufacturing, and ... Nanopatch™ needle-free drug delivery technology, have been named winners ... the Nanopatch Jet Coating Instrument , an advanced ... and product development.  The award was announced last evening ...
(Date:5/29/2015)... May 29, 2015 Research ... addition of the "Surgical/Operating Microscopes Market by ... 2020" report to their offering. ... microscopes market is poised to reach $806.6 million ... a CAGR of 12.3% from 2015 to 2020. ...
(Date:5/29/2015)... , May 29, 2015 /CNW/ - Covalon Technologies Ltd. ... medical technologies company, is delighted to announce its ... 31, 2015, which includes revenue for three months ... of $264,340. Revenue from advanced wound care product sales ... 2015 increased 24% to $1,742,672 compared to $1,400,065 ...
Breaking Medicine Technology:Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3
... Inc. has initiated Phase I/II clinical studies with ... Phase I/II safety and tolerability study in 18 ... cancer has begun,enrolment in the US. Secondary objectives ... vaccine to induce prostate antigen-specific immune,responses, as well ...
... of Clinical Oncology meeting indicate ... data., PRINCETON, N.J., June 3 Celator ... clinical trial in patients,with advanced colorectal cancer. CPX-1 ... on the company,s proprietary,CombiPlex(TM) technology. The results were ...
Cached Medicine Technology:BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine 2Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 2Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 3
(Date:5/29/2015)... Healthpointe is excited to announce that they are now ... in Orange County. The Supartz Therapy is a cost-effective, ... for patients with osteoarthritis, and will be administered by ... of Healthpointe. Supartz is an injection of made from ... a natural substance found in joint cartilage. Also known ...
(Date:5/29/2015)... 2015 The FSH Society ... science of the little-known and incurable disease, facioscapulohumeral ... the second FSHD Trial Preparedness Workshop. The Workshop, ... University of Rochester Medical Center in Rochester, New ... around the world, including representatives from industry, the ...
(Date:5/29/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 29, 2015 ... in the vulvar region and can cause significant physical, ... understands the major life altering disorder of Vulvodynia. The ... exclusion. At Women’s Excellence in Endometriosis, they realize that ... If a patient is experiencing any of these symptoms, ...
(Date:5/29/2015)... 29, 2015 The report ... provides comprehensive information on the therapeutic development ... pipelines by identifying new targets and MOAs ... report on H1 2015 pipeline review of ... and 13 figures, spread across 47 pages ...
(Date:5/29/2015)... Diego, CA (PRWEB) May 29, 2015 ... the deployment of their rewards based L-Style Select Program ... this exclusive program is limited to only 100 members ... opportunity to work one on one with fitness experts ... at no cost to them provided that they attain ...
Breaking Medicine News(10 mins):Health News:Healthpointe is Now Offering Supartz Joint Fluid Therapy at their Anaheim Clinic and La Mirada Clinic. 2Health News:International Conference Brings Together Key Stakeholders to Advance Clinical Trial Readiness for FSHD 2Health News:International Conference Brings Together Key Stakeholders to Advance Clinical Trial Readiness for FSHD 3Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Liporidex, a Sports Nutrition Supplement Brand, Is Searching For Members For Their Exclusive L-Style Select Program Which Rewards Members For Their Achievements 2
... HUM ) has,recently released three of its Stay Smart, Stay Healthy ... Stay Healthy videos have racked up more than 1.1 million,hits on ... remained,in the Top 5 videos in education worldwide through December. The ... , "We developed the Stay Smart, Stay ...
... the DNC bolsters firm,s national government affairs practiceWASHINGTON, ... nationally recognized political figure, presidential candidate and six ... an independent consultant exclusive to the government affairs ... Governor Dean will provide guidance to clients, particularly ...
... Than Half of America,s Youth Exceed Recommended Fat Intake; ... Makeover QUINCY, Mass., March 3 Continuing its tradition ... has expanded its NutriFilter sorting feature to include ... program recently launched at sister companies, Stop & ...
... genders regardless of weight issues, study finds , , TUESDAY, March ... than two hours a day or are otherwise inactive have ... , Researchers looked at more than 3,000 children whose ... age. , Each year, parents were asked about any ...
... Each day we have countless conversations with ourselves, and if ... what we say to ourselves is critical, judgmental, and often ... get it, we tend to make excuses and blame others, ... to our assumed shortcomings. Carol Messmer,s new ...
... 3 Catalyst Pharmaceutical Partners, Inc. (Nasdaq: ... develops and commercializes prescription drugs for the treatment of ... product development program. In order to extend its ... halt enrollment of new subjects into its ongoing U.S. ...
Cached Medicine News:Health News:Humana Releases Stay Smart, Stay Healthy Videos in Spanish 2Health News:Howard Dean to Join McKenna Long and Aldridge LLP 2Health News:Howard Dean to Join McKenna Long and Aldridge LLP 3Health News:Peapod Expands NutriFilter Shopping Tool With Healthy Ideas Program 2Health News:Peapod Expands NutriFilter Shopping Tool With Healthy Ideas Program 3Health News:2 Hours Glued to TV Doubles Kids' Asthma Risk 2Health News:'Conversations with Self: Discovering the Power of Your Inner Voice': Discover How to Find and Listen to an Inner Voice That Is Encouraging and Helpful 2Health News:Catalyst to Focus Resources on its Lead Indication for CPP-109; Cocaine Addiction 2Health News:Catalyst to Focus Resources on its Lead Indication for CPP-109; Cocaine Addiction 3
Features soft, low friction sheath that extends beyond the tip....
Designed to retain the desired curve during oral intubation....
Facilitates intubation of tracheal tubes....
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box....
Medicine Products: